$87.13
1.271.47%
Last update: Oct 26, 7:14 PM
Corcept Therapeutics Inc (CORT) Stock Price, Quote, News & History
CORTNASDAQ
Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.
You can purchase shares of Corcept Therapeutics (NASDAQ:CORT) through any online brokerage.
Other companies in Corcept Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Corcept Therapeutics has a consensus price target of $127.17.
The stock price for Corcept Therapeutics (NASDAQ: CORT) is $86.0325 last updated October 26, 2026 at 7:14 PM EDT.
There are no upcoming dividends for Corcept Therapeutics.
Corcept Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Corcept Therapeutics.
Corcept Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The...
